Emergent Biosolut Stock Probability Of Bankruptcy
| ER4 Stock | EUR 9.54 0.09 0.95% |
EMERGENT |
EMERGENT BIOSOLUT Company probability of distress Analysis
EMERGENT BIOSOLUT's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current EMERGENT BIOSOLUT Probability Of Bankruptcy | Over 53% |
Most of EMERGENT BIOSOLUT's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, EMERGENT BIOSOLUT is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of EMERGENT BIOSOLUT probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting EMERGENT BIOSOLUT odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of EMERGENT BIOSOLUT financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, EMERGENT BIOSOLUT has a Probability Of Bankruptcy of 53%. This is much higher than that of the sector and significantly higher than that of the Other industry. The probability of bankruptcy for all Germany stocks is notably lower than that of the firm.
EMERGENT Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses EMERGENT BIOSOLUT's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of EMERGENT BIOSOLUT could also be used in its relative valuation, which is a method of valuing EMERGENT BIOSOLUT by comparing valuation metrics of similar companies.EMERGENT BIOSOLUT is currently under evaluation in probability of bankruptcy category among its peers.
EMERGENT Fundamentals
| Current Valuation | 1.34 B | |||
| Price To Book | 0.43 X | |||
| Price To Sales | 0.42 X | |||
| Revenue | 1.12 B | |||
| EBITDA | (41.1 M) | |||
| Net Income | (223.8 M) | |||
| Total Debt | 448.5 M | |||
| Cash Flow From Operations | (34.1 M) | |||
| Number Of Employees | 18 | |||
| Market Capitalization | 1.91 B | |||
| Total Asset | 3.17 B | |||
| Z Score | 2.4 | |||
| Net Asset | 3.17 B |
About EMERGENT BIOSOLUT Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze EMERGENT BIOSOLUT's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EMERGENT BIOSOLUT using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EMERGENT BIOSOLUT based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in EMERGENT Stock
EMERGENT BIOSOLUT financial ratios help investors to determine whether EMERGENT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EMERGENT with respect to the benefits of owning EMERGENT BIOSOLUT security.